CNC
$32.81
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the United States.
Recent News
The Upside Debate: UnitedHealth's Consistency vs. Centene's Comeback
UNH's steady execution and diversified model face off against CNC's turnaround bid as cost pressures and policy shifts reshape upside potential.
Assessing Centene (CNC) Valuation After Prolonged Share Price Weakness And A Flagged Intrinsic Discount
Key recent performance signals Centene (CNC) has been on many investors’ screens after a series of weaker returns, including a 40.3% decline over the past year and a 14.9% drop year to date. Shares most recently closed at US$35.57. The move comes against a backdrop of mixed fundamentals, with annual revenue growth of 3.5% alongside a net income loss of US$6.7b and annual net income growth of 65.5%. See our latest analysis for Centene. The recent 1 month share price return of a 13.73% decline...
2 Growth Stocks with All-Star Potential and 1 Facing Challenges
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Centene Confronts ACA Membership Slide And Tests AI Driven Cost Controls
Centene CEO Sarah London highlighted a sharp decline in Affordable Care Act marketplace membership at the Barclays Healthcare Conference. The company is dealing with operational pressures tied to reduced Medicaid and ACA enrollments. AI tools are becoming a key part of Centene’s discussions with hospitals over suspected improper reimbursement practices. For investors watching NYSE:CNC, these membership and enrollment pressures come on top of a weak share price backdrop. Centene closed at...
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.